We used highly purified avian osteoclasts and isolated membranes from osteoclasts to study effects of tamoxifen, 4-hydroxytamoxifen, calmodulin antagonists, estrogen, diethylstilbestrol, and the anti-estrogen ICI 182780 on cellular degradation of 3 H-labeled bone in vitro and on membrane HCl transport. Bone resorption was reversibly inhibited by tamoxifen, 4-hydroxytamoxifen, and trifluoperazine with IC 50 values of ϳ1 M. Diethylstilbestrol and 17--estradiol had no effects on bone resorption at receptor-saturating concentrations, while ICI 182780 inhibited bone resorption at concentrations greater than 1 M. At these concentrations ICI 182780, like tamoxifen, inhibits calmodulin-stimulated cyclic nucleotide phosphodiesterase activity. Membrane Transport of Ca 2ϩ into and out of bone is critical for maintenance of serum calcium activity. This requires continuous bone turnover at variable rates, which is mediated by the osteoclast. However, skeletal mineral is also structurally vital, so osteoclastic activity is regulated by multiple factors, often acting in opposing directions. Several hormonal signals are involved in this regulation, including peptides and low molecular weight factors (1). Steroids including estrogens have major effects on bone turnover (2), but the receptors and intermediary signaling involved are not established. This study was performed to determine the mechanism of steroid-related effects on central biochemical elements of osteoclastic activity.A limiting biochemical step and the central regulated element of bone turnover is secretion of HCl to dissolve the bone mineral. This is driven by a vacuolar-like H ϩ -ATPase that is highly expressed in a unique osteoclastic organelle, the ruffled membrane (3). Multiple intermediary cell signals influence the activity of acid secretion, but one of critical interest is intracellular calcium activity and the ubiquitous calcium-binding protein, calmodulin. The unique acid-dependent dissolution of calcium salts produces high local extracellular calcium activity (4), which is reflected in an elaborate osteoclastic calcium regulatory mechanism including a calmodulin-dependent calcium ATPase (5), and factors influencing osteoclastic intracellular calcium activity such as matrix attachment (6). The vacuolarlike H ϩ -ATPase driving acid secretion in osteoclasts is also calmodulin-dependent, and osteoclasts concentrate calmodulin at the ruffled membrane (7).The anti-estrogenic compound, tamoxifen, reduces bone turnover (8), suggesting that tamoxifen may be a particularly useful tool to dissect osteoclast control pathways. Tamoxifen, a known calmodulin antagonist (9), is a triphenylethylene derivative with low toxicity and strong antitumor activity, particularly in breast cancer, properties ascribed to its anti-estrogenic activity (10). Tamoxifen may thus regulate osteoclastic activity by either calmodulin or steroid receptor interactions. In contrast to expectations that tamoxifen would cause bone loss because of anti-estrogenic properties (11), it preserves bo...